MedDataX Logo

High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department

NCT ID: NCT07278648

Last Updated: 2025-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-02-05

Study Completion Date

2026-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study aims to estimate the proportion of patients discharged from a hospital with a prescription for anticoagulant medication who subsequently visit the emergency department due to an adverse thrombotic or hemorrhagic event related to the treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Antithrombotic Treatment Hemorragic Event Anticoagulants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anticoagulant therapy

Patients who has been discharged from hospital with anticoagulant therapy

Antithrombotic therapy

Intervention Type OTHER

Anticoagulant treatment prescribed at discharge from an acute care unit

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Antithrombotic therapy

Anticoagulant treatment prescribed at discharge from an acute care unit

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients discharged from the Emergency Department (ED) and acute care units with an electronic prescription for at least one anticoagulant medication (new or ongoing), identified with the following codes:

B01AA - Vitamin K antagonists: warfarin and acenocoumarol

B01AB - Heparin group: low-molecular weight heparins such as enoxaparin, tinzaparin, bemiparin, …

B01AE - Direct thrombin inhibitors: dabigatran

B01AF - Direct factor Xa inhibitors: rivaroxaban, apixaban, edoxaban

Exclusion Criteria

* Those who are not part of the CSAPG healthcare area.
* Patients discharged from outpatient clinics, home hospitalization units, intermediate care, or residential facilities.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Consorci Sanitari de l'Alt Penedès i Garraf

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital de Vilafranca

Vilafranca del Penedès, Barcelona, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mar Saavedra

Role: CONTACT

Phone: 0034938960025

Email: [email protected]

Noemí Casaponsa

Role: CONTACT

Phone: 0034938960025

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mar Saavedra

Role: primary

Noemí Casaponsa

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CSAPG-79

Identifier Type: -

Identifier Source: org_study_id